T he initial Guide to the Primary Prevention of Cardiovascular Diseases was published in 1997 as an aid to healthcare professionals and their patients without established coronary artery disease or other atherosclerotic diseases. 1 It was intended to complement the American Heart Association (AHA)/American College of Cardiology (ACC) Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease (updated 2 ) and to provide the healthcare professional with a comprehensive approach to patients across a wide spectrum of risk. The imperative to prevent the first episode of coronary disease or stroke or the development of aortic aneurysm and peripheral arterial disease remains as strong as ever because of the still-high rate of first events that are fatal or disabling or require expensive intensive medical care. The evidence that most cardiovascular disease is preventable continues to grow. Results of long-term prospective studies consistently identify persons with low levels of risk factors as having lifelong low levels of heart disease and stroke. 3, 4 Moreover, these low levels of risk factors are related to healthy lifestyles. Data from the Nurses Health Study, 5 for example, suggest that in women, maintaining a desirable body weight, eating a healthy diet, exercising regularly, not smoking, and consuming a moderate amount of alcohol could account for an 84% reduction in risk, yet only 3% of the women studied were in that category. Clearly, the majority of the causes of cardiovascular disease are known and modifiable.
This 2002 update of the Guide acknowledges a number of advances in the field of primary prevention since 1997. Research continues to refine the recommendations on detec-tion and management of established risk factors, including evidence against the safety and efficacy of interventions once thought promising (eg, antioxidant vitamins). 6 This, in turn, has stimulated a large number of additional guidelines for specific demographic groups (eg, women), on individual risk factors (eg, diabetes, smoking), and for the primary prevention of stroke. In all of these guidelines, there is an increasing emphasis on further stratifying patients by level of risk and matching the intensity of interventions to the hazard for cardiovascular disease events. 7 Therefore, this 2002 update of the Primary Prevention Guide serves to integrate other guidelines and consensus statements developed since the initial Guide's approval. This Guide might be viewed as the entry point to the more specific and detailed recommendations and the rationale behind them. The recommendations, as presented in the accompanying tables, are therefore consistent with the following recommendations: Agency for Healthcare Policy and Research Guidelines on Treating Tobacco Use and Dependence 8 ; the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) 9 24 ; and the US Preventive Services Task Force evidence for use of aspirin in primary prevention. 25 The aspirin guidelines recommended here agree with the Task Force Report in the use of aspirin in persons at high coronary and stroke risk but use a Ն10% risk per 10 years rather than Ͼ6% risk over 10 years. This improves the likelihood of a positive balance of coronary risk reduction over bleeding and hemorrhagic stroke caused by aspirin. 26, 27 Although this Guide largely applies to adults, it does identify high-risk patients for whom screening and intervention in first-degree relatives (including children) would be an important aspect of primary prevention. However, this Guide will not provide specific recommendations for the reduction of cardiovascular risk in children and adolescents. This important issue will be the subject of a separate guide. However, a family-centered approach to primary prevention should be emphasized, inasmuch as it recognizes both the genetic and behavioral causes of the well-established familial aggregation of heart disease and stroke.
This Guide is intended to assist primary care providers in their assessment, management, and follow-up of patients who may be at risk for but who have not yet manifested cardiovascular disease. The continuing message is that adoption of healthy life habits remains the cornerstone of primary prevention, including the avoidance of tobacco (including secondhand smoke), healthy dietary patterns, weight control, and regular, appropriate exercise. An important role of healthcare providers is to support and reinforce these public health recommendations for all patients. Table 1 is presented to guide the identification and assess-ment of modifiable risk. The assessment of absolute cardiac risk is increasingly advocated by international organizations and by individual risk factor guidelines in the United States. 12, 25, 28 The Framingham database has been widely used, though we acknowledge that the multiple risk score may not apply equally to all sex, race, and ethnic groups. 29, 30 The use of more sophisticated technologies than a risk factor inventory and global risk score has been addressed, 31 and we conclude that most screening tests for occult atherosclerosis remain in the research arena, with the exception of the ankle-brachial blood pressure index. Similarly, those recommended interventions involving "nutriceutical" and pharmaceutical interventions in Table 2 have support from randomized clinical trials establishing their efficacy and safety. More controversial interventions, such as very low-fat diets, 32 dietary supplements, 6, 33 and potentially cardioprotective drugs other than aspirin require additional investigation in well-designed clinical trials in persons without established cardiovascular disease. The gap between which evidence-based interventions are recommended and what is actualized is large. 34, 35 Guidelines, even when based on the best available evidence from randomized, controlled trials, cannot be successfully implemented without acceptance by the entire healthcare team, including physicians, nurses, nutritionists, and other healthcare professionals. A physician-patient partnership must be forged, on the physician's part by assessing and communicating risk and by codeveloping with the patient a plan of preventive action. New tools for providers are available to foster this partnership, such as the AHA's Get With the Guidelines. 36 Information for the public on cardiovascular and stroke risk factors is available on the AHA web site. 37 The challenge for healthcare professionals is to engage greater numbers of patients, at an earlier stage of their disease, in comprehensive cardiovascular risk reduction with the use of interventions that are designed to circumvent or alleviate barriers to participation and adherence, so that many more individuals may realize the benefits that primary prevention can provide. The healthcare professional should create an environment supportive of risk factor change, including long-term reinforcement of adherence to lifestyle 12, 28 and in some risk scores, diabetes. 29, 30 Persons with diabetes or 10-y risk Ͼ20% can be considered at a level of risk similar to a patient with established cardiovascular disease (CHD risk equivalent). Equations for calculation of 10-y stroke risk are also available.
CHD indicates coronary heart disease. 
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Dietary intake
Goal: An overall healthy eating pattern.
Advocate consumption of a variety of fruits, vegetables, grains, low-fat or nonfat dairy products, fish, legumes, poultry, and lean meats. Match energy intake with energy needs and make appropriate changes to achieve weight loss when indicated. Modify food choices to reduce saturated fats (Ͻ10% of calories), cholesterol (Ͻ300 mg/d), and trans-fatty acids by substituting grains and unsaturated fatty acids from fish, vegetables, legumes, and nuts. Limit salt intake to Ͻ6 g/d. Limit alcohol intake (Յ2 drinks/d in men, Յ1 drink/d in women) among those who drink.
Aspirin
Goal: Low-dose aspirin in persons at higher CHD risk (especially those with 10-y risk of CHD Ն10%).
Do not recommend for patients with aspirin intolerance. Low-dose aspirin increases risk for gastrointestinal bleeding and hemorrhagic stroke. Do not use in persons at increased risk for these diseases. Benefits of cardiovascular risk reduction outweigh these risks in most patients at higher coronary risk. [25] [26] [27] Doses of 75-160 mg/d are as effective as higher doses. Therefore, consider 75-160 mg aspirin per day for persons at higher risk (especially those with 10-y risk of CHD of Ն10%).
Blood lipid management
Primary goal: LDL-C Ͻ160 mg/dL if Յ1 risk factor is present; LDL-C Ͻ130 mg/dL if Ն2 risk factors are present and 10-y CHD risk is Ͻ20%; or LDL-C Ͻ100 mg/dL if Ն2 risk factors are present and 10-y CHD risk is Ն20% or if patient has diabetes. Secondary goals (if LDL-C is at goal range): If triglycerides are Ͼ200 mg/dL, then use non-HDL-C as a secondary goal: non-HDL-C Ͻ190 mg/dL for Յ1 risk factor; non-HDL-C Ͻ160 mg/dL for Ն2 risk factors and 10-y CHD risk Յ20%; non-HDL-C Ͻ130 mg/dL for diabetics or for Ն2 risk factors and 10-y CHD risk Ͼ20%.
Other targets for therapy: triglycerides Ͼ150 mg/dL; HDL-C Ͻ40 mg/dL in men and Ͻ50 mg/dL in women.
If Initiate appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose or as indicated by near-normal HbA1c. First step is diet and exercise. Second-step therapy is usually oral hypoglycemic drugs: sulfonylureas and/or metformin with ancillary use of acarbose and thiazolidinediones. Third-step therapy is insulin. Treat other risk factors more aggressively (eg, change BP goal to Ͻ130/80 mm Hg and LDL-C goal to Ͻ100 mg/dL).
Chronic atrial fibrillation Goals: Normal sinus rhythm or, if chronic atrial fibrillation is present, anticoagulation with INR 2.0-3.0 (target 2.5).
Irregular pulse should be verified by an electrocardiogram. Conversion of appropriate individuals to normal sinus rhythm. For patients in chronic or intermittent atrial fibrillation, use warfarin anticoagulants to INR 2.0-3.0 (target 2.5). Aspirin (325 mg/d) can be used as an alternative in those with certain contraindications to oral anticoagulation. Patients Ͻ65 y of age without high risk may be treated with aspirin.
BP indicates blood pressure; CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; and INR, international normalized ratio. and drug interventions. Practice-based systems for risk factor monitoring, reminders, and support services need to be established, reimbursed, and otherwise supported by managed care organizations and third-party payers. Primary prevention, by its very nature, requires a lifetime of interactions that virtually define successful provider-patient relationships.
